CytoDyn raises $5M to push leronlimab deeper into solid tumors
What's the deal? CytoDyn (OTCQB: CYDY) has raised an additional $5 million from an anonymous private investor to fund clinical development of leronlimab, its lead monoclonal antibody targeting the CCR5 receptor. The shares were sold at $0.24 each with no accompanying warrants, the Vancouver, Washington-based company said on November 12, 2026.
What's the endgame? The proceeds will advance CytoDyn's colorectal cancer program, building on its Phase 2 CLOVER study. The company also plans to explore leronlimab in earlier lines of treatment and other solid tumors, including triple-negative breast cancer, pancreatic cancer, and glioblastoma.
Why now? The raise follows preliminary Phase 2 CLOVER results in metastatic colorectal cancer, which showed early ctDNA reductions and tumor shrinkage or stable disease in some patients. The investor, who had backed CytoDyn before, is doubling down as that early data emerges.
What could go wrong? The trial data remain interim and do not yet establish clinical benefit. The $5 million is also incremental — it follows a larger $16.5 million financing in September that the company said would fund operations into the second half of 2027.
Chief executive officer Robert E. Hoffman said the investment reflected "continued confidence in leronlimab" and would help the company "generate the evidence needed to inform future regulatory pathways."
The signal: For a clinical-stage biotech trading on the OTCQB, repeat backing from an existing investor signals endurance rather than a breakthrough. The real test for CytoDyn — and its backers — will be whether more mature trial results validate those early signals.
Read more: finance.yahoo.com
Image credit: Generated with Gemini
